Exelixis, Inc. (EXEL) vs Halozyme Therapeutics, Inc. (HALO)
Exelixis, Inc. and Halozyme Therapeutics, Inc. are both Biotechnology companies. Exelixis, Inc. is the larger, with a market value of $14.4B against $13.1B — 1.1× the size. Exelixis, Inc. trades at the lower P/E: 17.6× against 32.4×. Halozyme Therapeutics, Inc. grew revenue faster over the last twelve months: 41.2% against 9.23%. Exelixis, Inc. has the higher net margin (35.3% vs 24.9%) and the higher return on invested capital (60.5% vs 18.1%). Across the 22 metrics below, Exelixis, Inc. leads on 18 and Halozyme Therapeutics, Inc. on 4.
Valuation
Profitability
| Metric | EXEL | HALO | Biotechnology median |
|---|---|---|---|
| Gross margin | 96.48% | 82.42% | 65.16% |
| Operating margin | 39.88% | 35.90% | 0.00% |
| Net margin | 35.33% | 24.86% | 0.00% |
| Free cash flow margin | 47.55% | 48.46% | 0.00% |
| Return on equity | 44.39% | 173.67% | (57.72%) |
| Return on assets | 33.28% | 17.86% | (49.22%) |
| Return on invested capital | 60.45% | 18.13% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack